While much of the Trump administration has sparked controversy, the FDA’s consumer-first reforms may be remembered as its brightest legacy. From AI-driven drug reviews to bans on artificial dyes, the FDA’s agenda resonates with the public in ways few Trump-era policies have. In a presidency defined by polarization, the FDA under Commissioner Marty Makary has...
